ClinicalTrials.gg
RecruitingNCT07209878Updated Oct 7, 2025

68Ga-PSMA-11 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI

A Phase 2/3 interventional study of 68Ga-PSMA-11 in Prostate Cancer (Adenocarcinoma), sponsored by First Affiliated Hospital of Fujian Medical University. Recruiting at 1 site in China. Open to male participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-10-07.

Sponsored by First Affiliated Hospital of Fujian Medical University · Phase 2/3, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Registered 5 years 8 months after the study started (first participant enrolled Jan 2020, registered Sep 2025).
  • Started Jan 2020; still recruiting 6 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 49 studies testing gallium 68 PSMA-11 in Prostatic Neoplasms — 8 open to participants now, 11 under way, 3 of them phase 3. gallium 68 PSMA-11 · Prostatic Neoplasms.

Planned enrollment
19th of 49
100 · median 50
Started
2020
with 8 others
Phase 2/3
4 of 49
1 open now
Primary completion
2025-12
later than 5 of 10 live
Registered
47th of 49
by date
Lead sponsor
3 of 49
First Affiliated Hospital of Fujian Medical University

Among the 49 studies testing gallium 68 PSMA-11 in Prostatic Neoplasms, this one is the 19th largest by planned enrollment, is one of 9 that started in 2020, is one of 4 in phase 2/3, reaches primary completion later than 5 of the 10 other live ones, and was the 47th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

8 of the 49 studies testing gallium 68 PSMA-11 in Prostatic Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About gallium 68 PSMA-11

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 80 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies testing gallium 68 PSMA-11 in Prostatic Neoplasms, or all of them as a file.
02

Study summary

68Ga-PSMA-11 is a widely used radiotracer targeting PSMA. In this study, we investigated the diagnostic efficacy of 68Ga-PSMA-11 PET imaging (PET/CT or PET/MRI) in patients with newly diagnosed, treatment-naive prostate cancer, and performed a head-to-head comparison with multi-parameter magnetic resonance imaging (mpMRI).

Read the detailed description

68Ga-PSMA-11 is a radiotracer targeting PSMA. Previously, multiple clinical trials have validated the clinical applications of 68Ga-PSMA-11 PET. Meanwhile, multi-parametric magnetic resonance imaging (mpMRI) still holds a dominant position in the imaging diagnosis of prostate cancer. In this study, we will further evaluate the diagnostic performance of 68Ga-PSMA-11 positron emission tomography (PET/CT or PET/MRI) in newly diagnosed and untreated prostate cancer patients, with a head-to-head comparison to mpMRI.

03

Conditions studied

  • Prostate Cancer (Adenocarcinoma)

Keywords

  • PSMA
  • Prostate cancer
  • PET imaging
  • mpMRI
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -confirmed adenocarcinoma of the prostate.
  • No anti-tumor treatment received prior to the PET imaging.
  • Subjects provide signed and confirm that they are able and willing to comply with all protocol requirements.
  • Radical prostatectomy scheduled within 28 days after PET imaging

Exclusion criteria

Exclusion Criteria:

  • Patients with other malignant tumors
  • Subjects with any medical condition or other circumstance that, in the opinion of the investigator, compromise obtaining reliable data, achieving study objectives, or completion.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    68Ga-PSMA-11 PET/CT

    Intravenous injection of 68Ga-PSMA-11 with a dosage of 111-148 MBq (3-4 mCi), followed by PET/CT or PET/MRI acquisition according to standard methods

    Drug: 68Ga-PSMA-11

Interventions

06

What researchers measure

Primary outcomes

  1. Sensitivity of 68Ga-PSMA-11 Imaging to Detect Intraprostatic Tumors Relative to Histopathology in newly diagnosed, treatment-naive Prostate Cacner Participants

    Using histopathology from radical prostatectomy as the reference standard, validate the true positive detection rate of PET for prostate lesions. Two experienced nuclear medicine physicians, blinded to all other imaging and clinical history of the patients, independently assessed the PET images. Any disagreements were resolved by consensus.

    Time frame: Within 28 days of imaging, radical prostatectomy will occur.

  2. Specificity of 68Ga-PSMA-11 PET Imaging to Detect Intraprostatic Tumors Relative to Histopathology in newly diagnosed, treatment-naive Prostate Cacner Participants

    Using histopathology from radical prostatectomy as the reference standard, validate the true negative detection rate of PET for prostate lesions. Two experienced nuclear medicine physicians, blinded to all other imaging and clinical history of the patients, independently assessed the PET images. Any disagreements were resolved by consensus.

    Time frame: Within 28 days of imaging, radical prostatectomy will occur.

Secondary outcomes

  1. Comparison of Detection Rates for Intraprostatic Tumors Between 68Ga-PSMA-11 PET Imaging and mpMRI

    The number of intraprostatic lesions detected on imaging will be determined by each of independent readers. The sum of lesions per participant per tissue type and overall will be computed for each participant based on each reader's lesion count. This will be calculated from the 68Ga-PSMA-11 PET scan results as well as the mpMRI results.

    Time frame: Within 1-2 hours of 68Ga-PSMA-11 dosing, a whole body PET scan will be taken

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2020 (actual). Primary completion is estimated for Dec 2025, 71 months after the start.

Of 43 phase 2/3 interventional studies under Prostatic Neoplasms, half reached primary completion within 115 months of starting (the median), counting those still running; a quarter within 32. This study's planned 71 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2025
First posted
Oct 7, 2025
StartActual
Jan 10, 2020
Primary completionEst.
Dec 31, 2025
CompletionEst.
Jun 30, 2026
Last update
Oct 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07209878
Lead sponsor
First Affiliated Hospital of Fujian Medical University
Responsible party
Sponsor
First posted
Oct 7, 2025
Start date
Jan 10, 2020
Primary completion
Dec 31, 2025 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Oct 7, 2025

Study contacts

Weibing Miao, MD
Contact
miaoweibing@126.com
86-0591-87981618
Guochang Wang, MD
Contact
guochang1007@163.com
86-0591-87981619
Weibign Miao, MD
principal investigator · First Affiliated Hospital of Fujian Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gallium 68 PSMA-11

Start the discussion